Demant is a world-leading hearing healthcare and technology group built on a heritage of care, health and innovation since 1904. Today, the Group’s activities span the development and sales of hearing aids, delivery of hearing care through global network of hearing aid clinics, diagnostic instruments and services as well as audio solutions. We are a leader in innovation and we address markets that are supported by strong structural growth drivers and that are characterised by high levels of complexity in technology, distribution and regulatory environments. Over the last decades, the Group has grown significantly and now employs around 20,000 employees worldwide. In 2021, Demant delivered DKK 17.9 billion revenue and EBIT of DKK 3.5 billion while returning DKK 3.2 billion to shareholders in the form of share-buybacks.

Over the medium- to long-term, Demant aims to generate 7-10% growth in local currencies p.a. and to increase EBIT margins in each business area. As an integral part of the strategy, the company is committed to reinvest in the business to create innovative technology and add value-adding acquisitions. As a part of Demant’s capital allocation principles, all excess funds after acquisitions are returned to shareholders through share-buybacks.

The company is listed on Nasdaq Copenhagen and is a part of the OMX C25 index consisting of the 25 largest publicly traded companies in Denmark. With the William Demant Foundation holding over 50% of the shares in Demant A/S, Demant has a stable ownership structure that allows for the Group to focus on long-term value creation.


  • mathias-holten-møller

    Mathias Holten Møller

    Director, Head of Investor Relations
    Tel: +45 3917 7300
    Mob: +45 2924 9407

  • peter-pudselykke

    Peter Pudselykke

    Investor Relations Officer
    Tel: +45 3917 7300
    Mob: +45 2830 7638